Dendritic cell therapy -
Ovarian cancer (ovarian carcinoma)
Traditional treatment methods & modern immunotherapy
Ovarian cancer is one of the most challenging gynecological tumor diseases. Because early symptoms are usually subtle, the diagnosis is often only made in advanced stages.
Successful treatment requires a combination of surgery, chemotherapy, molecular diagnostics and, if necessary, additional immunological therapy approaches.
This section presents the classic treatment options as well as dendritic cell therapy (DZT) as a complementary immunological approach.
%20IMMUMEDIC%20Limited.jpg)
Classic treatment options for ovarian cancer
1. Surgery – a central component of the therapy
Surgery is crucial in cases of ovarian cancer, as it is essential to remove as much tumor tissue as possible.
Typical surgical procedures:
Removal of the ovaries and fallopian tubes
Removal of uterus, omentum, and affected lymph nodes
Peritoneal resections may be necessary in cases of tumor spread.
Goal: to achieve the most complete tumor reduction possible ("debulking").
2. Chemotherapy
Systemic chemotherapy usually follows the operation.
Standard regime:
Carboplatin + Paclitaxel
It is used as an adjuvant or in cases of relapse and is a central element of therapy.
3. Maintenance therapies / Targeted therapies
Molecular diagnostics (BRCA1/2, HRD status) plays an important role today.
Possible targeted therapies:
PARP inhibitors:
Olaparib
Niraparib
Rucaparib
They are used particularly in cases of BRCA mutations or HRD-positive tumors.
4. Antibody therapies
Targeted antibodies are used in selected situations:
Bevacizumab (VEGF inhibitor)
→ inhibits tumor angiogenesis and is often combined with chemotherapy.
5. Immunotherapy (Checkpoint Inhibitors)
Its effectiveness in treating ovarian cancer is currently limited, but is being intensively researched.
Dendritic cell therapy – an immunological approach to ovarian cancer
Dendritic cell therapy (DZT) is an individualized immunotherapy that aims to specifically activate T cells against tumor cells.
DZT procedure
Blood sample taken from the patient
Isolation of monocytes
Cultivation to dendritic cells
Loading with tumor antigens (e.g., tumor lysate)
Maturation into highly active immune cells
Return via intradermal injection
Dendritic cells present tumor characteristics to T cells – these can then specifically recognize tumor cells.
DZT as a complement to classic cancer therapy
Many patients use dendritic cell therapy as a complementary treatment to strengthen the immune system and to supplement a more individualized therapeutic strategy.
Combination options:
• DZT + Chemotherapy
Chemotherapy reduces tumor mass → DZT can support immunological targeting.
• DZT + PARP inhibitors
If BRCA/HRD is positive → the combination can influence the immunological environment.
• DZT + antibody therapy (bevacizumab)
It complements angiogenesis inhibition with immunological activation.
• DZT + Immune-boosting infusions
(e.g. glutathione, resveratrol, selenium, artesunate)
→ Strengthening the immune system during stressful therapies.
Goals of dendritic cell therapy in ovarian cancer
Activation of tumor-directed T cells
Support of immune surveillance
Complement to traditional treatments
Stabilization of the general condition
accompanying option to improve quality of life
Effectiveness varies from person to person and depends on tumor biology and immune status.
Dendritic cell therapy is a patient-specific immunological approach.
No promises of healing are made.